Discovery	O
and	O
Optimization	O
of	O
a	O
Novel	O
Triazole	B:C1689939
Series	I:C1689939
of	O
GPR142	O
Agonists	O
for	O
the	O
Treatment	O
of	O
Type	O
2	I:C0011860
Diabetes	I:C0011860
.	O

Discovery	O
and	O
Optimization	O
of	O
a	O
Novel	O
Triazole	O
Series	I:C1689939
of	O
GPR142	B:C1570380
Agonists	O
for	O
the	O
Treatment	O
of	O
Type	O
2	I:C0011860
Diabetes	I:C0011860
.	O

Discovery	O
and	O
Optimization	O
of	O
a	O
Novel	O
Triazole	O
Series	I:C1689939
of	O
GPR142	O
Agonists	B:C0243192
for	O
the	O
Treatment	O
of	O
Type	O
2	I:C0011860
Diabetes	I:C0011860
.	O

Discovery	O
and	O
Optimization	O
of	O
a	O
Novel	O
Triazole	O
Series	I:C1689939
of	O
GPR142	O
Agonists	O
for	O
the	O
Treatment	O
of	O
Type	B:C0011860
2	I:C0011860
Diabetes	I:C0011860
.	O

GPR142	B:C1570380
has	O
been	O
identified	O
as	O
a	O
potential	O
glucose	O
-	I:C2245393
stimulated	I:C2245393
insulin	I:C2245393
secretion	I:C2245393
(	O
glucose	O
-	I:C2245393
stimulated	I:C2245393
insulin	I:C2245393
secretion	I:C2245393
)	O
target	O
for	O
the	O
treatment	O
of	O
type	O
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
(	O
type	O
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
)	O
.	O

GPR142	O
has	O
been	O
identified	O
as	O
a	O
potential	O
glucose	B:C2245393
-	I:C2245393
stimulated	I:C2245393
insulin	I:C2245393
secretion	I:C2245393
(	O
glucose	O
-	I:C2245393
stimulated	I:C2245393
insulin	I:C2245393
secretion	I:C2245393
)	O
target	O
for	O
the	O
treatment	O
of	O
type	O
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
(	O
type	O
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
)	O
.	O

GPR142	O
has	O
been	O
identified	O
as	O
a	O
potential	O
glucose	O
-	I:C2245393
stimulated	I:C2245393
insulin	I:C2245393
secretion	I:C2245393
(	O
glucose	B:C2245393
-	I:C2245393
stimulated	I:C2245393
insulin	I:C2245393
secretion	I:C2245393
)	O
target	O
for	O
the	O
treatment	O
of	O
type	O
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
(	O
type	O
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
)	O
.	O

GPR142	O
has	O
been	O
identified	O
as	O
a	O
potential	O
glucose	O
-	I:C2245393
stimulated	I:C2245393
insulin	I:C2245393
secretion	I:C2245393
(	O
glucose	O
-	I:C2245393
stimulated	I:C2245393
insulin	I:C2245393
secretion	I:C2245393
)	O
target	O
for	O
the	O
treatment	O
of	O
type	B:C0011860
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
(	O
type	O
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
)	O
.	O

GPR142	O
has	O
been	O
identified	O
as	O
a	O
potential	O
glucose	O
-	I:C2245393
stimulated	I:C2245393
insulin	I:C2245393
secretion	I:C2245393
(	O
glucose	O
-	I:C2245393
stimulated	I:C2245393
insulin	I:C2245393
secretion	I:C2245393
)	O
target	O
for	O
the	O
treatment	O
of	O
type	O
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
(	O
type	B:C0011860
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
)	O
.	O

A	O
class	B:C1689939
of	I:C1689939
triazole	I:C1689939
GPR142	O
agonists	O
was	O
discovered	O
through	O
a	O
high	O
throughput	I:C0872187
screen	I:C0872187
.	O

A	O
class	O
of	I:C1689939
triazole	I:C1689939
GPR142	B:C1570380
agonists	O
was	O
discovered	O
through	O
a	O
high	O
throughput	I:C0872187
screen	I:C0872187
.	O

A	O
class	O
of	I:C1689939
triazole	I:C1689939
GPR142	O
agonists	B:C0243192
was	O
discovered	O
through	O
a	O
high	O
throughput	I:C0872187
screen	I:C0872187
.	O

A	O
class	O
of	I:C1689939
triazole	I:C1689939
GPR142	O
agonists	O
was	O
discovered	O
through	O
a	O
high	B:C0872187
throughput	I:C0872187
screen	I:C0872187
.	O

The	O
lead	B:C1254351
compound	I:C1254351
4	I:C1254351
suffered	O
from	O
poor	O
metabolic	O
stability	O
and	O
poor	O
solubility	O
.	O

Lead	O
optimization	O
strategies	O
to	O
improve	B:C0184511
potency	O
,	O
efficacy	O
,	O
metabolic	O
stability	O
,	O
and	O
solubility	O
are	O
described	O
.	O

This	O
optimization	O
led	O
to	O
compound	B:C1254351
20e	I:C1254351
,	O
which	O
showed	O
significant	O
reduction	O
of	O
glucose	O
excursion	I:C0428548
in	O
wild	O
-	I:C1520150
type	I:C1520150
but	O
not	O
in	O
GPR142	O
deficient	O
mice	O
in	O
an	O
oral	O
glucose	I:C0029161
tolerance	I:C0029161
test	I:C0029161
(	O
oral	O
glucose	I:C0029161
tolerance	I:C0029161
test	I:C0029161
)	O
study	O
.	O

This	O
optimization	O
led	O
to	O
compound	O
20e	I:C1254351
,	O
which	O
showed	O
significant	O
reduction	O
of	O
glucose	B:C0428548
excursion	I:C0428548
in	O
wild	O
-	I:C1520150
type	I:C1520150
but	O
not	O
in	O
GPR142	O
deficient	O
mice	O
in	O
an	O
oral	O
glucose	I:C0029161
tolerance	I:C0029161
test	I:C0029161
(	O
oral	O
glucose	I:C0029161
tolerance	I:C0029161
test	I:C0029161
)	O
study	O
.	O

This	O
optimization	O
led	O
to	O
compound	O
20e	I:C1254351
,	O
which	O
showed	O
significant	O
reduction	O
of	O
glucose	O
excursion	I:C0428548
in	O
wild	B:C1520150
-	I:C1520150
type	I:C1520150
but	O
not	O
in	O
GPR142	O
deficient	O
mice	O
in	O
an	O
oral	O
glucose	I:C0029161
tolerance	I:C0029161
test	I:C0029161
(	O
oral	O
glucose	I:C0029161
tolerance	I:C0029161
test	I:C0029161
)	O
study	O
.	O

This	O
optimization	O
led	O
to	O
compound	O
20e	I:C1254351
,	O
which	O
showed	O
significant	O
reduction	O
of	O
glucose	O
excursion	I:C0428548
in	O
wild	O
-	I:C1520150
type	I:C1520150
but	O
not	O
in	O
GPR142	B:C1723023
deficient	O
mice	O
in	O
an	O
oral	O
glucose	I:C0029161
tolerance	I:C0029161
test	I:C0029161
(	O
oral	O
glucose	I:C0029161
tolerance	I:C0029161
test	I:C0029161
)	O
study	O
.	O

This	O
optimization	O
led	O
to	O
compound	O
20e	I:C1254351
,	O
which	O
showed	O
significant	O
reduction	O
of	O
glucose	O
excursion	I:C0428548
in	O
wild	O
-	I:C1520150
type	I:C1520150
but	O
not	O
in	O
GPR142	O
deficient	O
mice	B:C0025929
in	O
an	O
oral	O
glucose	I:C0029161
tolerance	I:C0029161
test	I:C0029161
(	O
oral	O
glucose	I:C0029161
tolerance	I:C0029161
test	I:C0029161
)	O
study	O
.	O

This	O
optimization	O
led	O
to	O
compound	O
20e	I:C1254351
,	O
which	O
showed	O
significant	O
reduction	O
of	O
glucose	O
excursion	I:C0428548
in	O
wild	O
-	I:C1520150
type	I:C1520150
but	O
not	O
in	O
GPR142	O
deficient	O
mice	O
in	O
an	O
oral	B:C0029161
glucose	I:C0029161
tolerance	I:C0029161
test	I:C0029161
(	O
oral	O
glucose	I:C0029161
tolerance	I:C0029161
test	I:C0029161
)	O
study	O
.	O

This	O
optimization	O
led	O
to	O
compound	O
20e	I:C1254351
,	O
which	O
showed	O
significant	O
reduction	O
of	O
glucose	O
excursion	I:C0428548
in	O
wild	O
-	I:C1520150
type	I:C1520150
but	O
not	O
in	O
GPR142	O
deficient	O
mice	O
in	O
an	O
oral	O
glucose	I:C0029161
tolerance	I:C0029161
test	I:C0029161
(	O
oral	B:C0029161
glucose	I:C0029161
tolerance	I:C0029161
test	I:C0029161
)	O
study	O
.	O

These	O
studies	B:C2603343
provide	O
strong	O
evidence	O
that	O
reduction	O
of	O
glucose	O
excursion	I:C0428548
through	O
treatment	O
with	O
20e	O
is	O
GPR142	O
-	O
mediated	O
,	O
and	O
GPR142	O
agonists	O
could	O
be	O
used	O
as	O
a	O
potential	O
treatment	O
for	O
type	O
2	I:C0011860
diabetes	I:C0011860
.	O

These	O
studies	O
provide	O
strong	O
evidence	O
that	O
reduction	O
of	O
glucose	B:C0428548
excursion	I:C0428548
through	O
treatment	O
with	O
20e	O
is	O
GPR142	O
-	O
mediated	O
,	O
and	O
GPR142	O
agonists	O
could	O
be	O
used	O
as	O
a	O
potential	O
treatment	O
for	O
type	O
2	I:C0011860
diabetes	I:C0011860
.	O

These	O
studies	O
provide	O
strong	O
evidence	O
that	O
reduction	O
of	O
glucose	O
excursion	I:C0428548
through	O
treatment	O
with	O
20e	B:C1254351
is	O
GPR142	O
-	O
mediated	O
,	O
and	O
GPR142	O
agonists	O
could	O
be	O
used	O
as	O
a	O
potential	O
treatment	O
for	O
type	O
2	I:C0011860
diabetes	I:C0011860
.	O

These	O
studies	O
provide	O
strong	O
evidence	O
that	O
reduction	O
of	O
glucose	O
excursion	I:C0428548
through	O
treatment	O
with	O
20e	O
is	O
GPR142	B:C1723023
-	O
mediated	O
,	O
and	O
GPR142	O
agonists	O
could	O
be	O
used	O
as	O
a	O
potential	O
treatment	O
for	O
type	O
2	I:C0011860
diabetes	I:C0011860
.	O

These	O
studies	O
provide	O
strong	O
evidence	O
that	O
reduction	O
of	O
glucose	O
excursion	I:C0428548
through	O
treatment	O
with	O
20e	O
is	O
GPR142	O
-	O
mediated	O
,	O
and	O
GPR142	B:C1723023
agonists	O
could	O
be	O
used	O
as	O
a	O
potential	O
treatment	O
for	O
type	O
2	I:C0011860
diabetes	I:C0011860
.	O

These	O
studies	O
provide	O
strong	O
evidence	O
that	O
reduction	O
of	O
glucose	O
excursion	I:C0428548
through	O
treatment	O
with	O
20e	O
is	O
GPR142	O
-	O
mediated	O
,	O
and	O
GPR142	O
agonists	B:C0243192
could	O
be	O
used	O
as	O
a	O
potential	O
treatment	O
for	O
type	O
2	I:C0011860
diabetes	I:C0011860
.	O

These	O
studies	O
provide	O
strong	O
evidence	O
that	O
reduction	O
of	O
glucose	O
excursion	I:C0428548
through	O
treatment	O
with	O
20e	O
is	O
GPR142	O
-	O
mediated	O
,	O
and	O
GPR142	O
agonists	O
could	O
be	O
used	O
as	O
a	O
potential	O
treatment	O
for	O
type	B:C0011860
2	I:C0011860
diabetes	I:C0011860
.	O

